Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/infdis/jiac225 http://scihub22266oqcxt.onion/10.1093/infdis/jiac225 35877413!9384592!35877413     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Infect+Dis 2022 ; 226 (9): 1577-1587 Nephropedia Template TP {{tp|p=35877413|t=2022. Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection |pdf=|usr=}}{{35877413}} gab.com Text Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection JO: J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=35877413 #FOAvip Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is essential for diagnosis, treatment, and infection control. Polymerase chain reaction (PCR) fails to distinguish acute from resolved infections, as RNA is frequently detected after infectiousness. We hypothesized that nucleocapsid in blood marks acute infection with the potential to enhance isolation and treatment strategies. In a retrospective serosurvey of inpatient and outpatient encounters, we categorized samples along an infection timeline using timing of SARS-CoV-2 testing and symptomatology. Among 1860 specimens from 1607 patients, the highest levels and frequency of antigenemia were observed in samples from acute SARS-CoV-2 infection. Antigenemia was higher in seronegative individuals and in those with severe disease. In our analysis, antigenemia exhibited 85.8% sensitivity and 98.6% specificity as a biomarker for acute coronavirus disease 2019 (COVID-19). Thus, antigenemia sensitively and specifically marks acute SARS-CoV-2 infection. Further study is warranted to determine whether antigenemia may aid individualized assessment of active COVID-19. Twit Text FOAVip Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection ????J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=35877413 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35877413 #FOAvip English Wikipedia <ref>{{Cite pmid|35877413}}</ref> Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection #MMPMID35877413 Verkerke HP; Damhorst GL; Graciaa DS; McLendon K; O'Sick W; Robichaux C; Cheedarla N; Potlapalli S; Wu SC; Harrington KRV; Webster A; Kraft C; Rostad CA; Waggoner JJ; Gandhi NR; Guarner J; Auld SC; Neish A; Roback JD; Lam WA; Shah NS; Stowell SR J Infect Dis 2022[Nov]; 226 (9): 1577-1587 PMID35877413show ga Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is essential for diagnosis, treatment, and infection control. Polymerase chain reaction (PCR) fails to distinguish acute from resolved infections, as RNA is frequently detected after infectiousness. We hypothesized that nucleocapsid in blood marks acute infection with the potential to enhance isolation and treatment strategies. In a retrospective serosurvey of inpatient and outpatient encounters, we categorized samples along an infection timeline using timing of SARS-CoV-2 testing and symptomatology. Among 1860 specimens from 1607 patients, the highest levels and frequency of antigenemia were observed in samples from acute SARS-CoV-2 infection. Antigenemia was higher in seronegative individuals and in those with severe disease. In our analysis, antigenemia exhibited 85.8% sensitivity and 98.6% specificity as a biomarker for acute coronavirus disease 2019 (COVID-19). Thus, antigenemia sensitively and specifically marks acute SARS-CoV-2 infection. Further study is warranted to determine whether antigenemia may aid individualized assessment of active COVID-19. |*COVID-19[MESH] |Biomarkers[MESH] |COVID-19 Testing[MESH] |Humans[MESH] |Nucleocapsid[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection (epmc).pdf DeepDyve Pubget Overpricing